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Site-specific proteolytic processing plays important roles in the regulation of cellular activities. The histone
modification activity of the human trithorax group mixed-lineage leukemia (MLL) protein and the cell cycle
regulatory activity of the cell proliferation factor herpes simplex virus host cell factor 1 (HCF-1) are stimulated
by cleavage of precursors that generates stable heterodimeric complexes. MLL is processed by a protease called
taspase 1, whereas the precise mechanisms of HCF-1 maturation are unclear, although they are known to
depend on a series of sequence repeats called HCF-1PRO repeats. We demonstrate here that the Drosophila
homologs of MLL and HCF-1, called Trithorax and dHCF, are both cleaved by Drosophila taspase 1. Although
highly related, the human and Drosophila taspase 1 proteins display cognate species specificity. Thus, human
taspase 1 preferentially cleaves MLL and Drosophila taspase 1 preferentially cleaves Trithorax, consistent with
coevolution of taspase 1 and MLL/Trithorax proteins. HCF proteins display even greater species-specific
divergence in processing: whereas dHCF is cleaved by the Drosophila taspase 1, human and mouse HCF-1
maturation is taspase 1 independent. Instead, human and Xenopus HCF-1PRO repeats are cleaved in vitro by
a human proteolytic activity with novel properties. Thus, from insects to humans, HCF proteins have conserved
proteolytic maturation but evolved different mechanisms.
Site-specific proteolysis has emerged as an important mech-
anism contributing to the regulation of basic cellular processes
such as development (24), metabolism (3), cell cycle progres-
sion (7), and apoptosis (22). Site-specific proteolysis regulates
both physiological and disease processes, often by activating
latent functions.
In human cells, a number of nuclear proteins, such as the
trithorax group mixed-lineage leukemia (MLL) protein (11, 21,
35) and herpes simplex virus (HSV) host cell factor 1 (HCF-1)
(15, 31, 32), are synthesized as precursors that undergo pro-
teolytic maturation to generate stable, noncovalently associ-
ated heterodimeric complexes. The importance of these pro-
teolytic maturation processes is underscored by the finding that
the Drosophila homologs of these proteins, Trithorax (Trx) and
dHCF, also undergo proteolytic maturation (16, 18). Never-
theless, the cellular mechanism of proteolytic maturation is
completely known only for human MLL.
MLL is cleaved by a novel endopeptidase called taspase 1
that utilizes an N-terminal threonine generated by autoprote-
olysis as the nucleophile for polypeptide cleavage (10). For
HCF-1, autocatalytic processing of bacterially synthesized
HCF-1 has been observed (28), but the mechanisms of HCF-1
maturation in human cells remain to be clarified. Curiously, in
addition to sharing proteolytic maturation processes, MLL and
HCF-1 bind each other (36), and both play important roles in
the regulation of the cell division cycle (6, 23, 26, 30). These
relationships encouraged us to compare their proteolytic mat-
uration pathways along with those of the Drosophila Trx and
dHCF homologs.
Of these four proteins, MLL is the largest, consisting of
3,969 amino acids. It was originally discovered because the
gene encoding MLL is the site of chromosomal translocations
in human childhood leukemias (1, 5, 8). MLL possesses his-
tone H3 lysine 4 (H3K4) methyltransferase activity (20, 21)
and is required for maintaining proper Hox and Cyclin gene
expression (26, 37). MLL is cleaved by taspase 1 (10) at two
sites to generate the associated amino-terminal (MLLN) and
carboxy-terminal (MLLC) subunits (11, 21, 35). This proteol-
ysis enhances the H3K4 methyltransferase activity of the
MLLC subunit, which promotes Cyclin gene expression and cell
cycle progression (26).
The enzyme responsible for Trx cleavage is not known, but
it has been hypothesized that it is a homolog of taspase 1
because the region of cleavage (16) contains a putative taspase
1 recognition site (10, 35). The possible importance of Trx
cleavage for its biological function has been indicated by the
activity of a mutant Trx protein, called TrxE3, which contains a
271-amino-acid deletion (19) that spans the predicted process-
ing site and abrogates Trx protein maturation (16). Trx is
required to maintain proper expression of antennapedia and
bithorax complex genes during fly development (2). Interest-
ingly, trxE3 mutants display defective antennapedia but not
bithorax complex gene expression (25), suggesting a selective
role of Trx cleavage in its function.
HCF-1 is a 2,035-amino-acid chromatin-associated protein
that was first discovered as a transcriptional coactivator for
HSV immediate-early gene transcription, where it stimulates
formation of the viral VP16-induced transcriptional regulatory
complex (see reference 33 for a review). Proteolytic matura-
tion of HCF-1 involves multiple cleavages at any one of six
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centrally located 26-amino-acid repeats called HCF-1proteo-
lytic (HCF-1PRO) repeats, generating the associated amino-
terminal (HCF-1N) and carboxy-terminal (HCF-1C) subunits
(15, 31, 32). The HCF-1N and HCF-1C subunits play separate
roles in two key phases of the cell cycle: the HCF-1N subunit
promotes passage through the G1 phase, and the HCF-1C
subunit is necessary for proper mitosis and cytokinesis during
the M phase (14). Proteolytic processing is necessary to ensure
proper HCF-1 function, as HCF-1C subunit functions are in-
hibited if the HCF-1 precursor cannot be processed (14).
Consistent with the importance of HCF-1 proteolytic matu-
ration, the 1,500-amino-acid dHCF protein, although lacking
HCF-1PRO repeats, also undergoes proteolytic maturation to
generate associated dHCFN and dHCFC subunits (18). The
dHCFN and dHCFC subunits display considerable structural
similarity to the human HCF-1N and HCF-1C subunits (Fig. 1)
as well as functional conservation. Thus, as for the HCF-1N
subunit, the dHCFN subunit can associate with the HSV trans-
activator VP16 and stabilize the VP16-induced transcriptional
regulatory complex (18), as well as associate with the Drosoph-
ila cell cycle regulators dE2F1 (the homolog of human E2F1)
and dE2F2 (the homolog of human E2F4) (27).
Following our interest in HCF protein proteolytic matura-
tion and in the conservation of HCF proteins in animals, we
noted that dHCF, albeit not human HCF-1, contains a poten-
tial taspase 1 cleavage site within the region predicted by
Mahajan et al. (18) for cleavage. This observation has led us to
find that the dHCF and Trx proteins are both cleaved by the
Drosophila taspase 1 homolog, whereas human HCF-1 proteo-
lytic cleavage is independent of taspase 1. Thus, the Drosophila
and human trithorax group proteins share proteolytic matura-
tion pathways, while the Drosophila and human HCF proteins,
although conserving proteolysis as a maturation process, ma-
ture via different proteolytic mechanisms.
MATERIALS AND METHODS
Plasmid constructions and DNA template preparations. A full-length Dro-
sophila taspase 1 cDNA (LD05057) was obtained from the Drosophila Genomics
Resource Center, Bloomington, IN, and cloned into the pET-28a() His-tagged
bacterial expression vector (Novagen). The His-tagged full-length human taspase
1 cDNA bacterial expression vector and the vector for in vitro transcription/
translation containing wild-type and CS1/2-mutated MLL amino acids 2400 to
2900 have been described previously (10). The full-length dHCF cDNA cloned in
a T7 epitope-tagged Drosophila expression vector (pACXT-dHCF) was a kind
gift of Angus Wilson (New York University). For in vitro transcription/transla-
tion of the precursor, a PCR fragment encoding dHCF amino acids 733 to 1212
was amplified from pACXT-dHCF and inserted in the pNCITE vector (30). For
the Trx precursor, a PCR fragment encoding Trx amino acids 1973 to 2458 was
amplified by reverse transcription-PCR from SL2 cell RNA, verified by sequence
analysis, and inserted directly into the pGEM-T vector (Promega). Fragments
consisting of HCF-1 amino acids 686 to 1166 derived from either wild-type or
mutant pCGNHCFFL (31, 32) were PCR amplified using a forward primer
including the phage T7 promoter and -globin translational initiation codon and
directly used for in vitro transcription/translation. The Xenopus HCF-1 (xHCF-1)
precursor, corresponding to amino acids 1358 to 1653, was PCR amplified from
pCMV-SPORT6-xHCF-11358–1653 (clone ID 7653830; BioCat) as for HCF-1 and
directly used for in vitro transcription/translation. In vitro transcription/transla-
tion and [35S]methionine labeling were performed using the TNT T7 Quick
transcription/translation system (Promega) as recommended by the manufac-
turer. Mutants of the Trx CS2-like and dHCF CS1-like sites were generated by
QuickChange site-directed mutagenesis (Stratagene).
Taspase 1 protein expression. His-tagged human taspase 1 and Drosophila
taspase 1 were expressed in Escherichia coli BL21(DE5) cells and purified by Ni
affinity chromatography (QIAGEN) as recommended by the manufacturer. Pro-
teins eluted from the resin were dialyzed against phosphate-buffered saline, 25%
glycerol.
Cell culture and extracts. HeLa cells were grown at 37°C in Dulbecco’s
modified Eagle’s medium with 10% fetal bovine serum (FBS). Drosophila SL2
cells were grown at 25°C in Schneider’s medium (GIBCO) with 10% heat-
inactivated FBS. Nuclear and cytosolic extracts from HeLa and SL2 cells were
prepared as previously described (4). Wild-type or taspase 1/ mouse embry-
onic fibroblasts (MEFs) from day 12.5 embryos were grown as described previ-
ously (26). Extract was prepared by lysis in radioimmunoprecipitation assay
buffer with Complete protease inhibitor cocktail (Roche) on ice for 30 min and
clarified by centrifugation at 20,000  g for 20 min.
In vitro cleavage assays. Taspase 1 in vitro cleavage assays were performed as
previously described (10). For comparative experiments, recombinant human
taspase 1 and Drosophila taspase 1 activities were titrated on the respective
cognate MLL and Trx substrates and used in the amount required to cleave 50%
of the substrate (corresponding to 10 ng of human taspase 1 and 50 ng of
Drosophila taspase 1). For the xHCF-1 in vitro cleavage assay, 1 g of human
taspase 1 and Drosophila taspase 1 were used. Cell extract in vitro cleavage assays
were performed using 22 l of the indicated cell extract in a 30-l reaction
mixture and incubating reaction mixtures at 30°C for 8 h or the indicated time
period. HeLa cell extract heat treatment was at 65°C for 20 min, and protease
inhibitors were utilized at the final concentration of 0.5 mg/ml Pefabloc (Roche)
and 1 Complete protease inhibitor cocktail (Roche). The reaction mixtures
were resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), the resulting radioactive signals were visualized with a Typhoon
Trio imaging system and quantified with ImageQuant (Amersham Biosci-
ences).
RNAi and cell transfection. A 183-bp double-stranded RNA (dsRNA) (RNAi
1) and a 495-bp dsRNA (RNAi 2) against the Drosophila taspase 1 gene sequence
as well as a nonspecific firefly luciferase dsRNA were used for RNA interference
(RNAi). dsRNAs were synthesized with a MEGAscript T7 kit (Ambion), using
as templates PCR products amplified with primer pairs (RNA: 2), CAGTCGT
TCTGTGTCGGCTA and CTAGGAGCTGCAGGAAGGTG (RNA: 1) and
TGGGTTGCTCCATGGTG and TCCAGCGTACAGATCCTG each contain-
ing an additional 5 T7 promoter sequence. For dsRNA treatment, 1  106 SL2
cells were seeded in six-well plates in 1 ml of serum-free Schneider’s medium and
FIG. 1. Human and Drosophila MLL/Trx and HCF proteins.
(A) Schematic structures of human MLL and Drosophila Trx proteins.
Architectural elements are identified above the schematic: PHD, plant
homeodomain; FYRN, MLLN carboxy-terminal association element;
FYRC, MLLC amino-terminal association element; SET, histone H3
lysine 4 methyltransferase domain. The positions of the two taspase 1
cleavage sites (CS1 and CS2) are indicated as red and yellow arrow-
heads, respectively. Conserved regions in Trx are shown as for MLL.
The line labeled E3 indicates the region deleted in the mutant TrxE3
protein. (B) Schematic structures of human HCF-1 and dHCF pro-
teins. Architectural elements are identified above the schematic. HCF-
1KEL, Kelch repeat domain; Basic and Acidic, regions enriched in basic
and acidic residues, respectively; HCF-1PRO, HCF-1 proteolytic pro-
cessing repeats; Fn3, fibronectin type 3 repeats; NLS, nuclear local-
ization signal. Conserved regions in dHCF are shown in the same
colors; basic and acidic regions that display similar charge bias but not
sequence identity are shown in related colors. The position of the
dHCF CS1-like taspase 1 recognition site is indicated by the arrowhead
and dashed line.
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incubated at 25°C for 2 h in the presence of 15 g of dsRNA before addition of
2 ml of Schneider’s medium with 10% heat-inactivated FBS. dsRNA-treated cells
were collected after 96 h. For transient transfection, 2  106 untreated or
48-h-dsRNA-treated SL2 cells were transfected with 5 g of DNA using Cell-
fectin (Invitrogen) as described by the manufacturer. Cells were collected at 48 h
posttransfection. For collection, SL2 cells were washed with phosphate-buffered
saline, lysed in Laemmli SDS sample buffer, and subsequently analyzed by
immunoblot analysis.
Immunoblot analysis. Protein lysates were resolved by SDS-PAGE, trans-
ferred to nitrocellulose membrane, and probed with T7 tag monoclonal antibody
(Novagen), polyclonal HCF-1C antiserum (H12) (31), or polyclonal dHCFN
antiserum, followed by appropriate IRDye800-conjugated anti-mouse or
IRDye680-conjugated anti-rabbit immunoglobulin G (Rockland). The immuno-
reactive bands were detected by fluorescence with an Odyssey infrared imager
(LI-COR). The polyclonal dHCFN antiserum was raised in rabbits against a
15-amino-acid peptide (EGSDFVDPAFSSGER) corresponding to the N termi-
nus of dHCF and affinity purified with the peptide immunogen.
RESULTS
Figure 1 shows schematic representations of the human and
Drosophila MLL/Trx and HCF proteins highlighting conserved
sequence and structural elements. Figure 1A also shows the
positions of the two known taspase 1 cleavage sites in MLL,
called CS1 (QVD/GADD) and CS2 (QLD/GVDD) (10, 11,
35). By sequence similarity, Trx contains a CS2-like site
(QMD/GVDD) (10, 11, 35) and dHCF contains a CS1-like site
(QLD/GAGD), both of which lie in positions analogous to the
cleavage sites in the respective human homologs (i.e., MLL
CS1 and CS2 sites and HCF-1PRO sites). We therefore tested
whether the CS2-like Trx and CS1-like dHCF taspase 1 recog-
nition sites are substrates for taspase 1.
Trx and dHCF are cleaved by Drosophila taspase 1. In initial
experiments, we tested the ability of human taspase 1 to cleave
the Trx and dHCF proteins and found that the human protease
showed a strong preference for the human MLL substrate (see
below). Therefore, we tested the ability of the Drosophila ta-
spase 1 homolog to cleave Trx and dHCF substrates as shown
in Fig. 2. To facilitate this analysis, we generated for each
protein shorter precursor cleavage substrates that contain the
regions with the putative taspase 1 cleavage sites. Both wild-
type and cleavage site mutant substrates were used (Fig. 2A).
These precursors were synthesized in vitro in the presence of
[35S]methionine and incubated with recombinant Drosophila
taspase 1 purified from E. coli, and the products were sepa-
rated by SDS-PAGE. Figure 2B shows that Drosophila taspase
1 can cleave the wild-type Trx precursor (lanes 1 and 2) but not
the precursor carrying the mutation in the CS2-like site (lanes
3 and 4). These results suggest that, like its human homolog
MLL, Trx is cleaved by taspase 1 at the CS2-like cleavage site.
Similarly, as shown in Fig. 2C, Drosophila taspase 1 can effec-
tively cleave the wild-type dHCF precursor (lanes 1 and 2) but
not the CS1-like mutant precursor (lanes 3 and 4). These
experiments define the first heterologous protease for HCF
protein maturation, the Trx protease Drosophila taspase 1.
To characterize this dHCF protease further, we assessed
whether dHCF is cleaved at the taspase 1 cleavage site in vivo.
We transfected Drosophila SL2 cells with an epitope-tagged
expression vector encoding full-length wild-type and CS1-like
mutant recombinant dHCF (rdHCF) and assayed cleavage by
immunoblotting with an antitag antibody. As shown in Fig.
2D, synthesis of wild-type rdHCF resulted in an approxi-
mately 105-kDa N-terminal fragment (rdHCFN) (lane 2) (18),
whereas synthesis of the CS1-like mutant rdHCF led to an
approximately 180-kDa product, a size equivalent to that of the
full-length protein (rdHCFFL) (lane 3) (18). These results in-
dicate that dHCF is cleaved at a single taspase 1 recognition
site.
We also analyzed proteolytic maturation of endogenous
dHCF by generating an antibody directed to the N terminus of
the protein (see Materials and Methods). Immunoblot analysis
of the same SL2 extracts shown in Fig. 2D revealed that en-
dogenous dHCFN comigrates with the processed rdHCFN
(compare lanes 1 and 2 in Fig. 2D and E). With this antibody,
we could not detect any endogenous full-length dHCF protein,
but we could detect the ectopic CS1-like mutant rdHCFFL
(compare lane 3 with lane 1). The lack of endogenous full-
length dHCF indicates, as previously shown using a dHCFC
antibody (9), that dHCF is efficiently processed in Drosophila
cells.
To determine whether Drosophila taspase 1 is the sole pro-
tease responsible for dHCF processing in vivo, we depleted
Drosophila taspase 1 from Drosophila cells by RNAi. As shown
in Fig. 2F, independent treatment of SL2 cells with two differ-
ent taspase 1 dsRNAs (RNAi 1 and RNAi 2) led in each case
to the detection of dHCFFL (lanes 3 and 4) compared to
untreated (lane 1) or mock RNAi-treated (luciferase, lane 2)
cells. The levels of dHCFFL were limited, however, possibly
owing to high levels of stable dHCFN remaining from before
the RNAi treatment. In contrast, we observed prominent in-
hibition of rdHCF cleavage when the RNAi-induced Drosoph-
ila taspase 1 depletion was associated with concomitant
synthesis of dHCF by simultaneous transfection of the epitope-
tagged dHCF expression vector. Thus, as shown in Fig. 2G, in
taspase 1 RNAi-treated cells, rdHCF processing is significantly
reduced (lanes 3 and 4) compared to that in untreated (lane 1)
or mock RNAi-treated (lane 2) cells. In summary, our in vitro
and in vivo results indicate that Drosophila taspase 1 is respon-
sible for dHCF processing at a single site and indeed may be
the sole protease responsible for dHCF maturation. Thus, in
flies, where dHCF lacks HCF-1PRO repeats, HCF protein mat-
uration is apparently not autocatalytic as observed for an HCF-
1PRO repeat region of human HCF-1 synthesized in E. coli
(28).
dHCF is not an effective substrate for human taspase 1. We
were surprised to find that dHCF is a substrate of Drosophila
taspase 1, because Izeta et al. (12) have shown that dHCF is
not processed in hamster cells and yet such cells would be
expected to possess taspase 1. To explore this apparent dis-
crepancy, we compared directly the abilities of human and
Drosophila cell extracts to cleave the dHCF precursor. Indeed,
as the results of Izeta et al. (12) would suggest, the dHCF
precursor, albeit cleaved by a Drosophila SL2 extract, was not
effectively cleaved by a human HeLa cell extract, as shown in
Fig. 3A (compare lanes 2 and 3). This dissimilarity is likely the
result of intrinsic differences in the human taspase 1 and Dro-
sophila taspase 1 enzymes, because the same species-specific
activity was also observed with purified recombinant human
taspase 1 and Drosophila taspase 1 (compare lanes 5 and 6)
(see Materials and Methods for enzymatic activity normaliza-
tion). These results explain why Izeta et al. (12) did not observe
dHCF processing by using mammalian cells and emphasize the
VOL. 27, 2007 MLL/Trx AND HCF PROTEOLYTIC MATURATION 7065
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importance of using a homologous system to assay HCF pro-
tein processing (18).
The human and Drosophila taspase 1 enzymes have co-
evolved with their specific MLL/Trx substrates. The dHCF
Drosophila taspase 1 and human taspase 1 cleavage results
suggest that taspase 1 activity has changed during evolution. To
study this evolution further, we compared the human taspase 1
and Drosophila taspase 1 enzymes on homologous substrates:
precursors from the human MLL and Drosophila Trx proteins
(Fig. 3B). As shown in Fig. 3C, a human HeLa cell and a
Drosophila SL2 cell extract display enhanced activity on the
cognate MLL and Trx precursor, respectively (compare lanes 2
and 3 with lanes 5 and 6) (in this assay only MLL-CS2 cleavage
is indicated). Furthermore, purified recombinant human ta-
spase 1 and Drosophila taspase 1 display the same cognate
substrate preference (Fig. 3D, compare lanes 2 and 3 with
lanes 5 and 6). These results suggest that the taspase 1 enzymes
have coevolved with their substrates MLL and Trx.
Zhou et al. (38) have defined a human taspase 1 recognition
heptapeptide sequence. The MLL CS2 and Trx CS2-like sites
differ by a single amino acid (from QLDGVDD in MLL CS2 to
QMDGVDD in Trx). To examine the determinants responsi-
ble for the cognate enzyme substrate preference of Drosophila
taspase 1 on Trx, we converted the Trx CS2-like taspase 1 site
to the MLL CS2 sequence via a single amino acid change
(Fig. 3B). As shown in Fig. 3E, the humanized Trx precursor
[Trx(MLLCS2)] is still a better substrate for Drosophila taspase 1
than human taspase 1, indicating that the species-specific ta-
spase 1 selectivity observed here results from sequence differ-
ences that lie outside the so-far-identified heptapeptide recog-
nition sequence.
Human HCF-1 is not a taspase 1 substrate. HCF-1 is
cleaved at any one of the six HCF-1PRO repeats (15, 31), and
when the region containing all six sites is deleted (14, 32) or the
six sites are all individually inactivated by amino acid substitu-
tion (29), the protein is no longer cleaved. To study HCF-1
FIG. 2. Trx and dHCF are cleaved by Drosophila taspase 1.
(A) Schematic of Trx and dHCF cleavage precursors. The lines labeled
Pre indicate the region contained within each precursor. Wild-type
(wt) and mutant (mt) versions of the putative taspase 1 cleavage sites
are shown below. Note that the two diagrams are not drawn to the
same scale. (B) Drosophila taspase 1 (dTaspase1) proteolytic activity
on the Trx precursor. 35S-labeled wild-type (lanes 1 and 2) or CS2-like
mutant (lanes 3 and 4) Trx precursors were incubated for 2 h at 37°C
with (lanes 2 and 4) or without (lanes 1 and 3) purified recombinant
Drosophila taspase 1. Products were resolved by SDS-PAGE and re-
vealed by autoradiography. F, N-terminal cleavage product. A smaller
C-terminal fragment is not visible owing to the reduced specific activity
of this product. (C) Drosophila taspase 1 proteolytic activity on the
dHCF precursor. 35S-labeled wild-type (lanes 1 and 2) or CS1-like
mutant (lanes 3 and 4) dHCF precursors were incubated with (lanes 2
and 4) or without (lanes 1 and 3) purified recombinant Drosophila
taspase 1. Products were resolved by SDS-PAGE and revealed by
autoradiography. F, location of larger N-terminal and smaller C-ter-
minal cleavage products. (D) dHCF cleavage at the Drosophila taspase
1 cleavage site in vivo. SL2 cells were mock transfected (lane 1) or
transfected with wild-type (lane 2) or CS1-like mutant (lane 3) T7-
tagged full-length dHCF expression vector. Proteolysis by endogenous
protease was assessed by anti-T7 tag (T7) immunoblotting. rdHCFFL,
full-length rdHCF; rdHCFN, rdHCF N-terminal subunit. Molecular
mass markers are listed on the left. (E) Anti-dHCFN antibody (dHCFN)
reveals processing of endogenous dHCF. Endogenous dHCF proteol-
ysis of the samples shown in panel D was revealed by immunoblot
analysis with affinity-purified anti-dHCFN antibody. (F) RNAi deple-
tion of Drosophila taspase 1 impairs endogenous dHCF processing.
SL2 cells were mock treated (lane 1) or treated with luciferase (lane 2)
or two independent taspase 1 dsRNAs (RNAi 1 in lane 3 and RNAi 2
in lane 4) for 48 h before cleavage analysis by anti-dHCFN immuno-
blotting. (G) RNAi depletion of Drosophila taspase 1 impairs dHCF
processing. SL2 cells were treated with the indicated dsRNAs as in
panel F for 48 h before transfection of the T7-tagged full-length dHCF
expression vector. dHCF cleavage was analyzed 48 h after the trans-
fection by anti-T7 immunoblotting.
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proteolytic cleavage, we first asked whether the HCF-1PRO
repeat is a taspase 1 substrate. Therefore, we prepared an in
vitro HCF-1 protease substrate containing three of the six
HCF-1PRO repeats (HCF-1PRO repeats 1, 2, and 3, called
HCF-1rep123) (Fig. 4A) and incubated it with recombinant
human taspase 1. Figure 4B shows that human taspase 1 had
no effect on this HCF-1 precursor (compare lanes 1 and 2) at
a concentration that effectively cleaved the MLL precursor
(compare lanes 5 and 6), suggesting that taspase 1 is not an
HCF-1PRO repeat protease.
To further exclude the requirement of taspase 1 in HCF-1
maturation, we asked whether HCF-1 processing is affected by
the absence of taspase 1. Takeda et al. (26) have shown using
MEFs that MLL processing is disrupted in taspase 1/ knock-
out mice. In contrast, as shown in Fig. 4C, HCF-1 is processed
normally in both wild-type and taspase 1/ MEFs (compare
lanes 2 and 3), with the pattern of cleavage products being
identical to the one observed in a HeLa cell extract (lane 1).
Together, these results indicate that taspase 1 is not the pro-
tease responsible for HCF-1PRO repeat processing. Indeed,
taspase 1 is unlikely to be involved in HCF-1 processing gen-
erally, as there is no identifiable taspase 1 cleavage site in the
entire HCF-1 amino acid sequence.
A human cell activity cleaves HCF-1PRO repeats. To identify
an activity responsible for HCF-1PRO repeat processing, we
used a wild-type HCF-1rep123 substrate or substrates with
HCF-1PRO repeats 1 and 2 mutated either individually (HCF-
1repX23 and HCF-1rep1X3) or together (HCF-1repXX3) as
illustrated in Fig. 5A. As shown in Fig. 5B, in the absence of
cell extract, none of the precursors was effectively cleaved
(lanes 1, 3, 5, and 7). In the presence of HeLa cell extract,
however, each precursor was cleaved at the wild-type but not
mutated HCF-1PRO repeats (compare lanes 2, 4, 6, and 8),
displaying a cleavage pattern consistent with HCF-1PRO repeat
specific cleavage. These results suggest that HeLa cell extracts
possess an activity that can specifically cleave an HCF-1PRO
repeat precursor.
To establish the nature of this HCF-1PRO repeat enzymatic
activity, we performed a time course experiment using the
HCF-1rep123 precursor. As shown in Fig. 5C, under the same
assay conditions used for Fig. 5B, the HCF-1PRO repeat cleav-
age product increased with incubation time for approximately
8 h. Accumulation of the product resulting from cleavage at
the HCF-1PRO repeat 1 was quantified as shown in Fig. 5D.
These results suggest that in cell extracts the HCF-1PRO repeat
proteolytic cleavage is relatively slow but stable for 8 h.
The HeLa cell HCF-1PRO repeat proteolytic activity is heat
sensitive but protease inhibitor resistant. To characterize the
HCF-1PRO repeat protease further, we assayed the sensitivity
of the HeLa cell extract activity to heat and protease inhibitor
treatment as shown in Fig. 5E. The HeLa cell activity was
sensitive to heat treatment (compare lanes 1 to 3) but resistant
FIG. 3. Coevolution of human and Drosophila taspase 1 with their specific substrates. (A) Human taspase 1 versus Drosophila taspase 1
proteolytic activity on dHCF cleavage. Wild-type dHCF precursor was incubated without extract (lanes 1 and 4) or with HeLa (lane 2) and SL2
(lane 3) cytosolic extracts or recombinant human taspase 1 (lane 5) and Drosophila taspase 1 (lane 6). (B) Schematic of MLL and Trx cleavage
precursors. The line labeled Pre indicates the region contained within each precursor. The Trx(MLL CS2) precursor contains the Trx cleavage site
(QMDGVDD) changed to the MLL CS2 site sequence (QLDGVDD). (C) Human and Drosophila cell extract activities on MLL and Trx cleavage.
MLL (lanes 1 to 3) and Trx (lanes 4 to 6) precursors were incubated without extract (lanes 1 and 4) or with HeLa (lanes 2 and 5) or SL2 (lanes
3 and 6) cytosolic extracts. (D) Human taspase 1 and Drosophila taspase 1 activities on MLL and Trx cleavage. MLL (lanes 1 to 3) and Trx (lanes
4 to 6) precursors were incubated without taspase 1 (lanes 1 and 4) or with recombinant human taspase 1 (lanes 2 and 5) or Drosophila taspase
1 (lanes 3 and 6). (E) Human taspase 1 and Drosophila taspase 1 activities on humanized Trx(MLLCS2) precursor. The Trx(MLLCS2) precursor was
incubated without taspase 1 (lane 1) or with recombinant human taspase 1 (lane 2) or Drosophila taspase 1 (lane 3). For all cleavage products, black
dots indicate the N-terminal cleavage products; smaller, lower-specific-activity C-terminal fragments are not visible.
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to Pefabloc, a serine protease inhibitor (compare lanes 3 and
4) (an assay with thrombin and a substrate with a thrombin
cleavage site showed that the serine protease inhibitor was
active [data not shown]), and Complete, a serine and cysteine
protease inhibitor cocktail (compare lanes 3 and 5). Thus, the
HCF-1PRO repeat protease displays both sensitivity (heat) and
resistance (serine and cysteine protease inhibitors) to various
treatments. We note that the resistance of the HCF-1PRO
repeat protease to a serine protease inhibitor differentiates it
from the autocatalytic activity described by Vogel and Kristie,
which was serine protease inhibitor sensitive (28).
HCF protein maturation mechanism has changed during
evolution. The identification of taspase 1 as the protease re-
sponsible for dHCF maturation and the observation that hu-
man HCF-1 is cleaved by a different activity at the HCF-1PRO
repeats indicate that, from fly to human, HCF proteins have
conserved proteolytic maturation but evolved different mech-
anisms. These differences between flies and humans appear to
be generally specific to insects or vertebrates, as illustrated in
Fig. 6. Thus, the Apis mellifera (honeybee) HCF protein pos-
sesses a consensus taspase 1 cleavage site at the same relative
location as in the dHCF protein (Fig. 6A), suggesting that
taspase 1 cleavage of HCF proteins may be generally con-
served in insects. In parallel, a comparison of human, frog, and
fish HCF-1 proteins shows that the position (Fig. 6B) and
sequence (Fig. 6C) of the HCF-1PRO repeats have been very
highly conserved in these three distantly related vertebrate
species. Thus, between insects and vertebrates, there appears
to have been an evolutionary switch in HCF protein processing
mechanism that has been highly conserved within each group.
Interestingly, in some fish (e.g., F. rubripes) and frog (e.g., X.
tropicalis) species, in addition to the perfectly conserved HCF-
1PRO repeats there is a partially conserved taspase 1 cleavage
site (six-of-seven match to a heptapeptide consensus taspase 1
cleavage site) (38) located just C terminal of the last HCF-
1PRO repeat (Fig. 6B). This partially conserved taspase 1 cleav-
age site could represent an active site, indicating that in some
species HCF-1 could be processed by both taspase 1 and an
HCF-1PRO repeat protease. Alternatively, it could be inactive
and instead represent the vestige of an active taspase 1 cleav-
age site in an ancestral HCF-1 protein. To distinguish between
these two possibilities, we asked whether an xHCF-1 cleavage
precursor containing the partially conserved taspase 1 cleavage
site and the adjacent two HCF-1PRO repeats (xHCF-1rep89
[Fig. 6D]) could be a substrate for either taspase 1 and/or the
HCF-1PRO repeat protease. As shown in Fig. 6D, the xHCF-
1rep89 substrate is not cleaved by either Drosophila taspase 1
or human taspase 1 at concentrations that can effectively cleave
the dHCF precursor (compare lanes 1 to 3 and 4 to 6). Instead,
as for human HCF-1 (lanes 8 and 9), the xHCF-1rep89 pre-
cursor is cleaved by the HeLa cell extract at positions corre-
sponding to the HCF-1PRO repeats (compare lanes 4 and 7).
These data suggest that, like mammalian HCF-1 proteins,
xHCF-1 is not cleaved by taspase 1 but is instead processed at
the HCF-1PRO repeats by the same activity responsible for
human HCF-1 maturation. The ability of the human cell ex-
tract to cleave the Xenopus HCF-1PRO repeats provides func-
tional evidence of the high degree of conservation of the HCF-
1PRO repeat proteolytic process in vertebrates.
DISCUSSION
In this study, we have compared the proteolytic maturation
processes of two pairs of evolutionarily conserved proteins: the
FIG. 4. HCF-1 is not cleaved by taspase 1. (A) Schematic of HCF-1 cleavage precursor. The line labeled Pre indicates the region contained
within the precursor. Wild-type (wt) and mutated (mt) versions of the HCF-1PRO repeat 1 are shown below. (B) HCF-1PRO repeats are not evident
substrates for human taspase 1 (hTaspase1) cleavage. 35S-labeled wild-type (lanes 1, 2, 5, and 6) or mutated (lanes 3, 4, 7, and 8) HCF-1 and MLL
precursors were incubated with (lanes 2, 4, 6, and 8) or without (lanes 1, 3, 5, and 7) purified recombinant human taspase 1. F, larger N-terminal
and shorter C-terminal cleavage products. (C) taspase 1/ cells contain normally processed HCF-1. Wild-type (lane 2) and taspase 1/ (lane 3)
MEF lysates were resolved by 7% SDS-PAGE. Cleavage of endogenous HCF-1 was detected by anti-HCF-1C (HCF-1C) immunoblot analysis.
HeLa nuclear extract (lane 1) was used as an HCF-1 cleavage pattern control. —, HCF-1 precursor; F, HCF-1PRO repeat cleavage products.
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trithorax group proteins human MLL and Drosophila Trx and
the HCF proteins human HCF-1 and dHCF. We have shown
that, like MLL, the Drosophila Trx is a substrate for the taspase
1 protease. Interestingly, the enzyme-substrate specificity, i.e.,
human taspase 1 with MLL and Drosophila taspase 1 with Trx,
has coevolved. In contrast, with respect to HCF proteins, very
different proteolytic pathways have evolved. Thus, the dHCF
protein is cleaved by Drosophila taspase 1 but its human (and
Xenopus) HCF-1 counterparts are cleaved by what is likely an
unusual proteolytic activity.
Evolution of taspase 1 enzyme-substrate specificity. Hsieh et
al. (10) noted that sequences encoding the taspase 1 enzymes
have been conserved in vertebrates and insects but not in the
worm Caenorhabditis elegans and that, correspondingly, the
MLL/Trx developmental regulators in vertebrates and insects
but not in worms have taspase 1 recognition sites. Consistent
with this observation, Trx is indeed a taspase 1 substrate at its
CS2-like taspase 1 cleavage site. Examination of the activities
of the human and Drosophila taspase 1 enzymes on the MLL
and Trx proteins also revealed a more refined coevolution of
enzyme and substrate, as human taspase 1 is more active on its
cognate MLL substrate and Drosophila taspase 1 is more active
on its cognate Trx substrate. This observation suggests that the
presence of the taspase 1 enzyme and MLL/Trx protein mat-
uration have been conserved because the cleavage is critically
important for proper development (16, 19, 26). Nevertheless,
there is considerable flexibility in the interaction between pro-
tease and substrate, and for such enzyme-substrate coevolu-
tionary flexibility to be possible, it is likely that taspase 1 does
not possess a large number of essential targets.
We note with interest that vertebrates and insects display
common longitudinal body segmentation, which is lacking in C.
elegans, and that proper MLL and Trx maturation is function-
ally linked to proper homeodomain gene expression, which is
intimately involved in segmentation determination (10, 16, 19,
26). Consistent with the suggestion that MLL/Trx cleavage is
required to control the expression of genes involved in body
segmentation, in the sea urchin Strongylocentrotus purpuratus,
which, like C. elegans, is not longitudinally segmented, the Trx
homolog lacks an evident taspase 1 recognition site and there
is no evident taspase 1-encoding gene (data not shown).
Although HCF proteins are not known to be involved in
FIG. 5. HCF-1PRO repeats are faithfully processed by human cell extracts. (A) Schematic of HCF-1 cleavage precursors. The line labeled Pre
indicates the region contained within each precursor. These HCF-1 precursors contain the first three HCF-1PRO repeats in a wild-type version
(HCF-1rep123) or with mutated repeat 1 (HCF-1repX23), mutated repeat 2 (HCF-1rep1X3), or mutated repeats 1 and 2 (HCF-1repXX3).
Products corresponding to full-length precursor (Pre) and N-terminal cleavage products for HCF-1PRO repeats 3, 2, and 1 are shown below.
(B) HeLa cell extract cleavage of HCF-1PRO repeats.
35S-labeled HCF-1 precursors from panel A were incubated without (lanes 1, 3, 5, and 7) or
with (lanes 2, 4, 6, and 8) nuclear HeLa cell extract. Numbers on the right of each panel indicate the N-terminal cleavage product derived from
the indicated HCF-1PRO repeat; x indicates the missing cleavage product corresponding to the mutated HCF-1PRO repeat; C-terminal fragments
are not visible owing to their reduced specific activity. (C) Time course of the HeLa cell extract proteolytic activity. 35S-labeled HCF-1rep123
precursor was incubated with nuclear HeLa cell extracts for the indicated periods of time. (D) Quantification of time course data. The relative
accumulation of HCF-1PRO repeat 1 cleavage product from panel C was quantified to represent HCF-1PRO repeat cleavage activity over time.
(E) Characterization of the HeLa cell proteolytic activity. 35S-labeled HCF-1rep123 precursor was incubated without extract (lane 1) or with
nuclear HeLa cell extract (lanes 2 to 5) that was heat treated (lane 2), untreated (lane 3), or treated with Pefabloc (lane 4) or Complete protease
inhibitor (PI) mixture (lane 5).
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FIG. 6. Evolution of HCF protein maturation. (A) HCF protein maturation in insects. Top, schematic representation of dHCF. The taspase
1 cleavage site is indicated by the arrowhead. Bottom, charge profiles of the fly Drosophila melanogaster and the honeybee Apis mellifera HCF
proteins. Peaks above zero indicate basic regions, and peaks below zero indicate acidic regions; basic and acidic regions are shown in blue and red,
respectively. For each protein, sequences of taspase 1 cleavage sites are indicated above arrowheads. (B) HCF protein maturation in vertebrates.
Top, schematic representation of human HCF-1. Segments corresponding to the basic and acidic regions and to the HCF-1PRO repeats are
indicated above the schematic. Bottom, charge profiles of the human Homo sapiens, frog Xenopus tropicalis, and fish Fugus rubripes HCF proteins
as in panel A. For each protein, the region corresponding to the HCF-1PRO repeats is overlined. Sequences corresponding to partially conserved
taspase 1 cleavage sites are indicated above arrowheads; in red is indicated the residue that does not match the taspase 1 site consensus.
(C) Sequence conservation of the HCF-1PRO repeats in vertebrates. An alignment of fish (top), frog (center), and human (bottom) HCF-1PRO
repeats is shown. The human HCF-1PRO repeats are numbered as in reference 15. Residues matching a consensus based on the most frequent
residue at each position are shaded. Positions in the consensus sequences for which a conserved residue cannot be defined are indicated by dashes.
Underlined positions indicate sequence conservation among HCF-1PRO repeats of all three species. F, residues important for human HCF-1PRO
repeat cleavage in vivo (32). (D) In vitro cleavage of xHCF-1. Top, schematic representation of xHCF-1. The line labeled Pre indicates the region
contained in the cleavage precursor. The dashed line indicates the imperfect taspase 1 cleavage site. Bottom, xHCF-1 precursor (xHCF-1rep89)
was incubated without additions (lane 4) or with either Drosophila taspase 1 (dTaspase1) (lane 5), human taspase 1 (hTaspase1) (lane 6), or HeLa
cell extract (lane 7). dHCF (lanes 1 to 3) and human HCF-1 (hHCF-1rep123; lanes 8 and 9) precursors are shown as positive controls for taspase
1 (dHCF) and HCF-1PRO repeat (hHCF-1rep123) cleavage. F, HCF protein cleavage products.
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regulating segmentation, invertebrate HCF proteins display
species-specific patterns of proteolytic maturation that follow
the Trx proteins. Thus, in Drosophila, dHCF and Trx are both
cleaved by Drosophila taspase 1, and in the honeybee the HCF
and Trx homologs possess taspase 1 recognition sites. In con-
trast, as with the Trx homologs, the sea urchin and worm HCF
proteins do not possess evident taspase 1 recognition sites
(data not shown); indeed, worm HCF does not undergo pro-
teolytic maturation (34). We suggest that in invertebrates, the
HCF and Trx proteins coevolved taspase 1-induced matura-
tion. In contrast, in vertebrates, HCF-1 proteins took on a very
different proteolytic maturation mechanism. Nevertheless, the
parallels between MLL/Trx and HCF protein maturation sug-
gest that in addition to regulation of the cell cycle, HCF-1 may
also play a role in regulation of genes involved in segment
determination.
HCF-1 is likely cleaved by an unusual protease. We have
described an enzymatic activity in HeLa cell extracts that spe-
cifically cleaves the HCF-1PRO repeat. We do not know at this
time the precise relationship between the HeLa cell activity
described here and the HCF-1 autocatalytic activity described
previously (28), but we note some differences between the two
activities. The autocatalytic activity, which depends on se-
quences within the HCF-1C region, results in cleavage at not
only HCF-1PRO repeats but also an additional site, called 102,
which lacks evident HCF-1PRO repeat sequence similarity and
is located just C terminal of the sixth HCF-1PRO repeat (15,
28). This autocatalytic site is, however, not used in vivo when
the HCF-1PRO repeats are inactivated by mutation or deletion
(14, 29, 32), and we have not observed 102 site cleavage using
a precursor substrate spanning this site in the HeLa cell extract
assay (F. Capotosti and W. Herr, unpublished results). Thus, in
both HeLa cells and HeLa cell extracts, HCF-1 proteolytic
maturation appears to be HCF-1PRO repeat specific. We also
note that, unlike the autocatalytic 102 site activity, which is
sensitive to the serine protease inhibitor Pefabloc (28), the
HeLa cell HCF-1PRO repeat activity is resistant to this protease
inhibitor (Fig. 5E). Clarifying the relationship between the
HeLa cell activity described here and the HCF-1 autocatalytic
activity will require further investigation.
Whatever the relationship, however, the properties of the
HCF-1PRO repeat protease are likely to be unusual. As shown
in Fig. 6C, there are 16 amino acid residues over 19 positions
that are identical among the HCF-1PRO repeat consensus se-
quence of the fish, frog, and human HCF-1 proteins, an im-
pressive level of sequence conservation for a proteolytic rec-
ognition sequence. Furthermore, as described previously (32),
alanine substitutions at 12 positions over 18 of the human
HCF-1PRO repeat 2 affect HCF-1PRO repeat cleavage in HeLa
cells (Fig. 6C), a surprisingly large sequence requirement for
proteolytic cleavage. Given this extensive sequence conserva-
tion and sequence requirements, we suggest that the functional
HCF-1PRO repeat element reflects the assemblage of different
recognition sequences for (i) the protease itself and (ii) acces-
sory factors that could regulate proteolysis. Such accessory
factors could directly recruit or stimulate the protease or could
reflect enzymes that modify the HCF-1PRO repeat (e.g., by
phosphorylation or glycosylation) to regulate cleavage. What-
ever the reason, the large size of the HCF-1PRO repeat results
in considerable specificity, as we have been unable to find a
match to the HCF-1PRO repeat in any other protein sequence
found in public protein databases, suggesting that in toto the
mechanisms of HCF-1PRO repeat cleavage are unique to
HCF-1 maturation.
Alternate mechanisms of HCF protein cleavage result in
HCFN and HCFC subunits of similar structure. The evolution-
ary comparisons shown in Fig. 6 indicate that although the
mechanisms of HCF protein maturation have switched be-
tween insects and vertebrates, the end results of proteolytic
processing are similar. To illustrate this point, Fig. 6A and B
show charge profiles for the two insect (fly and honeybee) and
three vertebrate (fish, frog, and human) HCF proteins. These
profiles show that the insect and vertebrate HCF proteins all
contain basic and acidic regions at corresponding positions.
This conservation of amino acid composition is consistent with
the important cellular functions these regions have been shown
to possess in human HCF-1: G1 phase progression in the case
of the basic region (30) and M phase progression (13), tran-
scriptional activation (17), and chromatin association (13) in
the case of the acidic region. We note with interest that
whether the HCF protein is cleaved by taspase 1, as appears to
be the case with the insect HCF proteins, or at the HCF-1PRO
repeats, as appears to be the case in the vertebrate proteins,
the cleavage site(s) is always positioned between the basic and
acidic regions. Thus, although the mechanism for HCF protein
proteolysis has changed during evolution, the resulting HCFN
and HCFC subunits are very similar in structure.
How and why might a transition from taspase 1- to HCF-
1PRO repeat-dependent HCF-1 proteolysis have evolved? The
unexpected switch in proteolytic processing mechanism be-
tween insect and vertebrate HCF proteins leads to the ques-
tions of how and why. Concerning how the HCF-1PRO repeats
may have arisen, we note with interest that the six HCF-1PRO
repeats in fish and human HCF-1 are all encoded by a single
large exon of 1,477 bp in human. (The nine repeats in X.
tropicalis are encoded by two exons [five in the first and four in
the second], which may have resulted from a duplication of the
six-repeat-containing fish/human exon [Fig. 6C].) We imagine
that an HCF-1 progenitor acquired the six HCF-1PRO repeats
as a single genetic element by recombination, perhaps trans-
position, prior to vertebrate evolutionary divergence.
Concerning why a switch may have occurred, one possible
explanation is that the region containing the HCF-1PRO re-
peats has been evolutionarily selected as an additional plat-
form for protein-protein interactions, as Vogel and Kristie (29)
have shown that the transcriptional coactivator/corepressor
FHL2 interacts with nonprocessed HCF-1, stimulating tran-
scription of an HCF-1 target gene. This interaction between
HCF-1PRO repeats and cofactors could allow the modulation
of HCF-1 processing and activity. Another possible explana-
tion is that, with an HCF-1PRO repeat protease, HCF-1 protein
maturation has become independent from taspase 1 and thus
from MLL/Trx maturation. This could result in a more flexible
regulation of these two important cell cycle regulators. In any
case, however, the importance of HCF-1PRO repeat processing
during vertebrate evolution is underscored by the remarkable
similarity among the repeats themselves in one species (e.g.,
human) and between vertebrates as divergent as fish and hu-
man (Fig. 6C).
In conclusion, in human and fly, the MLL/Trx and HCF
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proteins have conserved the process of proteolytic maturation,
but the MLL/Trx process coevolved with the cognate taspase 1
proteases, whereas HCF-1 and dHCF have apparently evolved
very different proteolytic pathways. Whatever the reason for
the evolutionary change to HCF-1PRO repeat-dependent pro-
cessing in vertebrates, it is evident that the HCF-1PRO repeats
are unusual cleavage sites, and it is likely that the protease
responsible for their cleavage has unusual properties.
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